Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/24/2868290/0/en/Pharming-Group-to-report-first-quarter-2024-financial-results-on-May-8.html
https://www.globenewswire.com/news-release/2024/04/24/2868259/0/en/Pharming-to-be-honored-as-Industry-Innovator-at-National-Organization-for-Rare-Disorders-NORD-2024-Rare-Impact-Awards.html
https://www.globenewswire.com/news-release/2024/04/19/2866305/0/en/Pharming-Group-announces-the-repurchase-of-outstanding-125-million-convertible-bonds-due-2025.html
https://www.globenewswire.com//news-release/2024/03/14/2845977/0/en/Pharming-Group-reports-fourth-quarter-and-full-year-2023-financial-results.html
https://www.globenewswire.com//news-release/2024/02/08/2825707/0/en/Pharming-Group-to-participate-in-February-investor-conferences.html
https://www.globenewswire.com//news-release/2024/01/08/2805036/0/en/Pharming-Group-announces-updated-full-year-2023-guidance-and-Joenja-U-S-launch-update.html
https://www.globenewswire.com//news-release/2023/12/13/2795234/0/en/Pharming-Group-announces-development-plans-for-leniolisib-for-additional-primary-immunodeficiencies-PIDs.html
https://www.globenewswire.com//news-release/2023/12/13/2795234/0/en/Pharming-Group-announces-development-plans-for-leniolisib-for-additional-primary-immunodeficiencies-PIDs.html
https://www.globenewswire.com//news-release/2023/11/21/2783690/0/en/Pharming-announces-first-patient-dosed-in-pediatric-clinical-trial-for-children-aged-1-to-6-years-for-leniolisib.html
https://www.globenewswire.com//news-release/2023/11/10/2778337/0/en/Pharming-Group-provides-updates-on-EMA-regulatory-review-of-leniolisib-MAA-and-plans-to-file-for-UK-regulatory-approval.html